The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FTRE | -34.95% | N/A | N/A | -62% |
| S&P | +16.9% | +95.99% | +14.39% | +54% |
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $710.30M | 7.2% |
| Gross Profit | $113.90M | -1.6% |
| Gross Margin | 16.04% | -1.4% |
| Market Cap | $447.07M | -78.6% |
| Market Cap / Employee | $0.03M | 0.0% |
| Employees | 15.5K | -13.9% |
| Net Income | -$374.90M | -277.5% |
| EBITDA | $8.70M | 145.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $81.20M | -35.7% |
| Accounts Receivable | $739.20M | 15.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.15B | -3.0% |
| Short Term Debt | $87.20M | 545.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.19% | -26.4% |
| Return On Invested Capital | -0.82% | -3.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $14.30M | -94.6% |
| Operating Free Cash Flow | $21.80M | -92.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.23 | 1.11 | 0.50 | 0.52 | -60.28% |
| Price to Sales | 0.65 | 0.62 | 0.25 | 0.16 | -77.43% |
| Price to Tangible Book Value | -1.87 | -1.77 | -0.67 | -0.43 | -82.53% |
| Price to Free Cash Flow TTM | 9.22 | 8.15 | 7.05 | 4.69 | -86.25% |
| Enterprise Value to EBITDA | 240.88 | -382.35 | -888.07 | 184.75 | -211.55% |
| Free Cash Flow Yield | 10.8% | 12.3% | 14.2% | 21.3% | 627.36% |
| Return on Equity | -14.6% | -17.5% | -61.6% | -100.5% | 607.28% |
| Total Debt | $1.20B | $1.20B | $1.29B | $1.24B | 3.15% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
